Home › Funds › Paradigm Biocapital Advisors LP › ALNY

Paradigm Biocapital Advisors LP position in ALNY

ALNYLAM PHARMACEUTICALS INC · Health Care

Paradigm Biocapital Advisors LP reported holding 480,000 shares of ALNY (ALNYLAM PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$144.5M, representing 2.71% of its reported portfolio and ranking #12 among its reported holdings. Paradigm Biocapital Advisors LP first reported this position in Q2 2026.

Latest position (Q2 2026)480.00K sh
Reported value held$144.49M
Portfolio Weight2.71%
First reportedQ2 2026
Last changeNew
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Paradigm Biocapital Advisors LP's ALNY position evolved

Paradigm Biocapital Advisors LP first disclosed a stake in ALNY in Q2 2026 at 480,000 shares (US$144.5M).

Quarter by quarter

QuarterSharesValueChange
Q2 2026 480.00K $144.49M New

About ALNY and 13F data

ALNY (ALNYLAM PHARMACEUTICALS INC) is a Health Care company. 36 other funds we track also report a position in ALNY — the largest reported positions include T. Rowe Price Investment Management, Inc. (US$1.70B), Baillie Gifford & Co (US$734.5M), Orbis Allan Gray Ltd (US$598.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ALNY

All ALNY fund holders →

FAQ

How long has Paradigm Biocapital Advisors LP held ALNY?

Paradigm Biocapital Advisors LP has disclosed ALNY holdings in 1 of the last 1 reported quarters, going back to Q2 2026.

What is Paradigm Biocapital Advisors LP's current position in ALNY?

As of Q2 2026, Paradigm Biocapital Advisors LP holds 480.00K shares of ALNY (ALNYLAM PHARMACEUTICALS INC), valued at $144.49M, representing 2.71% of its reported portfolio and ranking #12.

Has Paradigm Biocapital Advisors LP been buying or selling ALNY?

In the latest 13F filing (Q2 2026), Paradigm Biocapital Advisors LP newly opened its position in ALNY.

Which other funds hold ALNY?

Other major institutional holders of ALNY include T. Rowe Price Investment Management, Inc., Baillie Gifford & Co, Orbis Allan Gray Ltd, among 36 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.